Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06816004 · ClinicalTrials.gov registry record · NA

Noninvasive Vagal Nerve Stimulation

A NA study of Multiple Sclerosis, sponsored by NYU Langone Health.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT06816004: Recruiting NA study of Multiple Sclerosis, sponsored by NYU Langone Health.

NCT06816004 is a NA study of Multiple Sclerosis that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 30 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06816004, a NA study of Multiple Sclerosis, is actively recruiting participants, sponsored by NYU Langone Health.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

Growing evidence suggests that vagal nerve stimulation (VNS) may be novel and effective in the management of the symptom burden of multiple sclerosis (MS) potentially by reducing inflammation and emotional distress, therefore improving overall well-being. We will complete a pilot study comparing transcutaneous auricular vagus nerve stimulation (taVNS) and transcutaneous cervical vagus nerve stimulation (tcVNS) to a standard intervention of dorsolateral prefrontal cortex (DLPFC) transcranial direct current stimulation (tDCS) as an active control. The primary outcome will be feasibility and the preliminary efficacy data concerning self-reported symptom reduction to inform the design of an intervention, and estimated power needed to complete a larger sham-controlled RCT. We will also measure heart rate variability (HRV), an easily obtained biomarker of vagus nerve stimulation (VNS), in correspondence to intervention response.

Primary Outcome

Assessed among participants in the taVNS or tcVNS arms only.

Conditions Studied

Interventions

  • DEVICE Remotely Supervised Transcranial Direct Current Stimulation (RS - tDCS)
  • DEVICE Remotely Supervised Transcutaneous Auricular Vagus Nerve Stimulation (RS - taVNS)
  • DEVICE Remotely Supervised Transcutaneous Cervical Vagus Nerve Stimulation (RS - tcVNS)

Study Locations (1)

New York

  • NYU Langone Health - New York

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-08-20
Est. Completion 2026-05-05
Phase NA
NYU Langone Health

1,164 total trials

What NCT06816004 shows while recruiting

NCT06816004 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 3 interventions - of which Remotely Supervised Transcranial Direct Current Stimulation (RS - tDCS) is the first listed.

NCT06816004 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06816004 about?

NCT06816004 is a clinical study titled "Noninvasive Vagal Nerve Stimulation". Growing evidence suggests that vagal nerve stimulation (VNS) may be novel and effective in the management of the symptom burden of multiple sclerosis (MS) potentially by reducing inflammation and emotional distress, therefore improving overall well-being. We will complete a pilot study comparing tr...

What is the current status of trial NCT06816004?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-08-20. Estimated completion is 2026-05-05.

What conditions does trial NCT06816004 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

What interventions are being tested in trial NCT06816004?

The interventions under investigation include: Remotely Supervised Transcranial Direct Current Stimulation (RS - tDCS) (DEVICE), Remotely Supervised Transcutaneous Auricular Vagus Nerve Stimulation (RS - taVNS) (DEVICE), Remotely Supervised Transcutaneous Cervical Vagus Nerve Stimulation (RS - tcVNS) (DEVICE).

Who is sponsoring clinical trial NCT06816004?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06816004 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06816004's enrollment target sits among peer trials

30 222nd of 315 higher than 76 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06816004, the US trial registry maintained by the National Library of Medicine. NCT06816004 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.